The 5-year relative survival rate of men with PCa is 98%, which may be attributed to the early test of prostate-specific antigen (PSA) combined with prostate needle biopsy and advanced therapy strategies (2). The gene discussed is KLK3; the disease is posterior cortical atrophy.